Latest Medical Imaging News

Pro Medicus delivered a robust FY26 with 28% underlying revenue growth, a surge in new contract wins worth $407 million, and a 25% increase in fully franked dividends, underpinned by strong AI product development and rapid implementations.

Radiopharm Theranostics is gearing up for a pivotal Phase 3 trial of its brain metastases imaging agent RAD101, following strong Phase 2b results and an upcoming FDA meeting to finalise trial design.

Pro Medicus’ US subsidiary Visage Imaging has landed a 7-year, A$23 million contract to deploy its cloud-based Visage 7 platform across St. Luke’s Health System, marking a further expansion in North America.

Enlitic has launched its cloud-based Ensight platform in the US through a phased deployment with Radiology Imaging Associates, generating an initial annual recurring revenue of approximately US$50,000 and setting the stage for broader expansion.

Integral Diagnostics (ASX: IDX) posted strong preliminary FY26 results with revenue nearing $790 million and operating EBITDA up 30%, while announcing Jenny Martin as incoming CFO amid leadership transitions.

Philips has officially declared compatibility for Imricor’s interventional MR devices with its magnetic resonance systems, enabling commercial clinical use and collaboration at a leading cardiology congress.

CurveBeam AI has launched a Share Purchase Plan offering eligible shareholders a 10% discount on new shares, aiming to raise up to $2 million alongside a pending $5 million placement.

Micro-X has named Brian Gonzales as its new CEO, initiating a strategic reset focused on medical CT technology. The company also secured $8 million in convertible note commitments to fund development and extend its financial runway through FY27.

Singular Health deepens US healthcare foothold with ongoing Triple-S contract talks, PNS licence expansion, and Miami-Dade educational rollout, supported by a solid $10.1 million cash reserve.

Enlitic slashed its net operating cash outflow by 76% in Q2 FY26 and secured binding commitments for a A$15 million conditional placement alongside convertible note conversions, positioning the company with a pro forma cash balance of about A$18 million and a debt-free balance sheet.

Cyclopharm’s Technegas® has been named the preferred ventilation agent in new US lung imaging guidelines, marking the first update in 14 years and potentially accelerating adoption across American hospitals.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.